Quetiapine Misuse and Abuse: Is It an Atypical Paradigm of Drug Seeking Behavior?

Sean Hyungwoo Kim  
*University of Kentucky*, sean.kim@uky.edu

Gayoung Lee  
*Johns Hopkins University*

Eric Kim  
*University of Alabama, Birmingham*

Hyejin Jung  
*University of Texas, El Paso*

Jongwha Chang  
*University of Texas, El Paso*, jchang@utep.edu

Follow this and additional works at: [https://uknowledge.uky.edu/ipop_facpub](https://uknowledge.uky.edu/ipop_facpub)

Part of the *Pharmacy Administration, Policy and Regulation Commons*

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Repository Citation
[https://uknowledge.uky.edu/ipop_facpub/1](https://uknowledge.uky.edu/ipop_facpub/1)

This Article is brought to you for free and open access by the Pharmaceutical Outcomes and Policy at UKnowledge. It has been accepted for inclusion in Institute for Pharmaceutical Outcomes and Policy Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Quetiapine Misuse and Abuse: Is It an Atypical Paradigm of Drug Seeking Behavior?

Digital Object Identifier (DOI)
https://doi.org/10.4103/2279-042X.200987

Notes/Citation Information
Published in Journal of Research in Pharmacy Practice, v. 6, issue 1, p. 12-15.

© 2017 Journal of Research in Pharmacy Practice

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

This article is available at UKnowledge: https://uknowledge.uky.edu/ipop_facpub/1
Review Article

Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug Seeking Behavior?

Sean Kim¹, Gayoung Lee², Eric Kim³, Hyejin Jung⁴, Jongwha Chang⁵

¹Institute of Pharmaceutical Outcomes and Policy, University of Kentucky, Lexington, Kentucky, USA
²Wolfe Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, USA
³Department of Biology, University of Alabama, Birmingham, Alabama, USA
⁴Department of Social Work, University of Texas, El Paso, Texas, USA
⁵Department of Pharmacy Practice, University of Texas, El Paso, Texas, USA

Received: July 2016. Accepted: November 2016.

INTRODUCTION

Atypical antipsychotics (AAs), also known as second-generation antipsychotics, are a group of antipsychotic medications used to treat serious mental illness such as bipolar disorder, schizophrenia, and anxiety disorder.[1] Currently, there are 11 commonly prescribed AA medications approved by the Food and Drug Administration (FDA): aripiprazole, asenapine, clozapine, iloperidone, lurasidone, olanzapine, olanzapine/fluoxetine, paliperidone, quetiapine, risperidone, and ziprasidone.[1] Since the introduction of the first AA drug, clozapine, in the 1970s, the advent of AAs has provided new treatment options for patients with serious psychiatric conditions.[2-4] AAs are often considered safer than typical antipsychotics, they are associated with a decreased risk of neuroleptic malignant syndrome and extrapyramidal symptoms such as tardive dyskinesia (a movement disorder), tremor, and dystonia (muscle spasm and contractions).[1,5]

Recently, increasing off-label use of AAs outside FDA-approved indications has been evident.[1] In 2013, the Drug Utilization Sub-committee of Australian Department of Health showed evidence of antipsychotic use among people aged 20–59 for the treatment of conditions other than schizophrenia or bipolar disorder.[6] In the same year, the National Prescribing Service identified issues with off-label use of antipsychotics as means of behavior control in people with dementia in residential aged-care and other specialized-care facilities.[7]

A series of case reports of AA abuse was reported in literature more than a decade ago,[8,9] and several studies documented quetiapine as the most commonly abused AA.[10-13] Although off-label prescribing in psychiatry is a common practice, changing trends in AA off-label use and the associated risks need to be scrutinized due to a potential correlation between previous substance abuse history (i.e., schizophrenia or bipolar disorder) and likelihood of misusing and abusing...
AAs.[14,15] Use of AAs in patients with substance abuse has been noted where drug-seeking behaviors were observed in correctional facility settings.[10] Quetiapine abuse may be more prevalent among prisoners since commonly abused drugs are not readily available due to limited pharmaceutical formulary.[10]

Misuse and abuse (MUA) of pharmaceuticals is associated with medications that produce euphoria or other desirable effects such as relaxation or alertness.[16] Therefore, AAs are not generally considered drugs of abuse. However, AAs are being used to either enhance the effects of illicit substances such as cocaine and marijuana or counter their adverse effects.[17]

**Quetiapine in the Treatment of Substance Abuse**

AAs are commonly prescribed to aid in treating withdrawal symptoms from abused substances (i.e., alcohol, cocaine, benzodiazepines, or opioids) while increasing abstinence. However, this treatment showed inconsistent evidence with varying degrees of success.[18-22] Quetiapine decreased psychiatric symptoms such as sleeplessness and anxiety for alcoholic patients with comorbid conditions such as bipolar disorder or schizoaffective disorder when patients were provided with 300–800 mg/day for 16 weeks following detoxification treatment.[14] One possible speculation is that quetiapine alleviated mood symptoms and anxiety associated with withdrawal symptoms.

It is interesting to note that when patients do not have comorbid psychiatric conditions, AAs used to treat substance abuse did not show any significant benefit versus placebo.[1] One possible explanation is that high comorbidity rate is thought to originate from the common biological roots of schizophrenia and bipolar disorders. Dopamine sensitivity in schizophrenic patients was found to make them more susceptible to the rewarding effect of the substance.[14]

**Quetiapine Off-Label Use**

The use of AAs in clinical practice has extended beyond FDA-approved indications and off-label uses; there have been signs that corroborate the emergence of quetiapine as the most commonly abused AA.[23] These signs include existence of street names and values in the black market, diversion in prisons and other institutionalized settings, users seeking drug by feigning symptoms, and reports of intravenous or intranasal use of the drug.[10] Some street names include “Susie-Q,” “baby-heroine,” and “squirrel,” when used in conjunction with other drugs of abuse, combinations are referred to as Maq-ball (quetiapine + marijuana) or Q-ball (quetiapine + cocaine or heroin).[10,13,24,25] Numerous early reports and case studies focused on illicit use in incarcerated populations, which are at high risk of quetiapine MUA.[11-13] In most cases, MUA of AAs are shown to be associated with forensic settings such as incarceration, court-ordered hospitalization, or other oversight by the legal system. Numerous case reports and several systematic studies have shown that quetiapine MUA is not confined to penal populations; it also occurs in other settings such as psychiatric inpatients, outpatients, and patients attending drug treatment clinics.[14,25,36]

Although the magnitude of AA MUA is unclear, this emerging trend has gained recognition. Patients often misuse AAs in an attempt to self-medicate and ameliorate unpleasant symptoms of withdrawal. Substance abusers may take AAs to counteract the effects of the addicted agent. In addition, polydrug users who were prescribed numerous psychoactive drugs are associated with illegally obtaining quetiapine in combination with other drugs.[27-29]

**Quetiapine Abuse and Adverse Health Outcomes**

Quetiapine abuse is most frequently related to its sedative and anxiolytic characteristics.[10] It is proposed that the motivation for quetiapine MUA is “self-medication” for symptoms of anxiety and sleep withdrawal rather than euphoric effects.[14] Nationally representative data presented by a recent study of emergency department (ED) visits involving MUA of quetiapine further highlight this emerging trend. The Drug Abuse Warning Network (DAWN) has contributed evidence stating MUA of quetiapine is warranted.[16] The study found that high frequency of quetiapine-related ED visits involving MUA occurs among the noninstitutionalized general population, suggesting the need for evaluating potential MUA of quetiapine by patients.[16]

There is a growing concern within the medical community in regard to the potential harm from prescribing quetiapine for its off-label use as well as dependence potential. In addition, there have been a number of international high-profile court cases in the media regarding quetiapine-related death involving either drug-drug interactions or overdose.[6,30] Little is known about the reasons for off-label prescribing, but a historical perspective of sedative and hypnotic prescribing trends may explain this escalating use. The transition from barbiturates from early to mid-20th century (1920–1950s) to benzodiazepines in the 1960s were mainly due to safety concerns.[24,31] Benzodiazepines use became more prevalent, but there have been increasing safety concerns over benzodiazepines, in particular alprazolam.[25] It is interesting to note that patients whose symptoms with insomnia may be able to benefit from sedating characteristic of second-generation antipsychotics. More importantly, long-term use of both benzodiazepines and barbiturates has shown dependence with withdrawal symptoms, tolerance, and drug-seeking behavior despite a maladaptive pattern of substance abuse.[33] Quetiapine, on the other hand, poses very low dystonia and extrapyramidal side effects. Hence, it is predicted that this seemingly safer profile is what makes quetiapine a more attractive treatment option than other antipsychotics. However, some known side effects such as metabolic disturbances such as weight gain, diabetes, and dyslipidemia are prominent in second-generation AAs.[34,35] Clozapine and olanzapine carry significantly higher risk than other AAs, whereas aripiprazole, lurasidone, and ziprasidone are associated with the lowest risk of metabolic disturbances.[36-41]
**DISCUSSION: PUBLIC HEALTH IMPLICATION**

From a public health perspective, how does MUA of AAs pose a public health challenge? When AAs are used for recreational/ self-medication purposes without medical supervision, there are negative health consequences as MUA poses health risks as well as ED visits.[16] According to Mattson et al., ED visits involving MUA of quetiapine accounted for 52% of visits due to any antipsychotics. In addition, the greatest contributor to ED visits was quetiapine where 62% of visits were due to second-generation AAs.[15] These findings suggest the need for heightened vigilance on potential MUA of quetiapine as well as other AAs. In addition to personal health risks, quetiapine MUA may pose negative public health implications. Providing AAs to malingerers in individualized forensic settings affects mental health budgets as well as our available public health resources. Injudicious prescription of quetiapine is a rising problem as health-care providers need to have tighter regulations and clinical guidelines to follow. There is a need to consider quetiapine as a potential candidate to be classified as a scheduled controlled substance if there are robust research findings in the future.[17,42]

Tarasoff and Osti suggest that there is evidence for quetiapine being commonly diverted from prescribed users for its cash street value.[29] Hence, clinicians need to be especially concerned about MUA when prescribing quetiapine to patients with comorbid mental health conditions for self-treating substance MUA as well as quetiapine’s potential for abuse. Clinicians should be aware of the fact that patients who are looking out for quetiapine should pay close attention to potential substance abuse and dependence. This emerging public health problem merits continued surveillance and awareness on the part of prescribers and the public health community of the potential for misuse of AAs.[16]

**CONCLUSION**

Quetiapine MUA is increasing due to the fact that clinicians are prescribing fewer benzodiazepines, barbiturates, and stimulant drugs because of their addictive characteristics.[14] Quetiapine has its unique motivation for anxiolytic and sedative effects without dependence. However, several case studies have found that quetiapine causes seeking behaviors observed in substance use disorder in the absence of definitive mechanism of action of quetiapine’s reinforcing properties. Therefore, it is imperative to gather robust evidence to support or refute increasing off-label use of AAs as well as dependence.

**AUTHORS’ CONTRIBUTION**

Sean Kim was responsible for idea and draft writing for the manuscript. Gayoung Lee was responsible for literature search as well as draft writing for the manuscript. Eric Kim was responsible for formatting and editing the overall manuscript. Hyejin Jung was responsible for writing public health implication section. Jongwha Chang was responsible for the overall supervision of the editing, manuscript writing, as well as all the support for literature search and providing resources.

**FINANCIAL SUPPORT AND SPONSORSHIP**

Nil.

**CONFLICTS OF INTEREST**

There are no conflicts of interest.

**REFERENCES**


